Oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe, chronic cancer pain: Challenges in the context of hepatic impairment
Brian H Le, Ghauri Aggarwal, Carol Douglas, Michael Green, Amanda Nicoll, Sam Ahmedzai
Asia-Pacific Journal of Clinical Oncology | WILEY | Published : 2021
Opioids such as oxycodone are recommended in the management of moderate-to-severe, chronic cancer pain. All opioids can potentially cause constipation, which may be a significant barrier to their use. Multiple randomised clinical trials have shown that the use of naloxone as a peripherally acting mu-opioid receptor antagonist, in combination with oxycodone can prevent or reduce opioid-induced constipation while having equivalent analgesic efficacy to oxycodone alone. However, clinical experience has shown that unexpected events may occur in some patients when unrecognized liver impairment is present. We describe the underlying biological reasons and propose simple, but effective steps to avo..View full abstract
Administrative and medicalwriting support was provided byMsVasugi Sanjayan (Allori Pty Ltd., Australia) and Dr Anja Becher (Sydney, Australia) and was funded by Mundipharma Australia.